Non-small cell lung cancer (NSCLC) represents the most widespread (around 90%) of all lung cancer in patients.1–5 During the past few years, the epidermal growth factor receptor (EGFR) signaling pathway as a therapeutic target in NSCLC has gained more recognition.6 Inhibitors of the tyrosine kinase (TKIs) that affect the epidermal growth factor receptor (EGFR) are very effective against most EGFR mutations with a good therapeutic window. Here, EGFR is linked to non-small cell lung carcinoma.